236 related articles for article (PubMed ID: 32086605)
1. Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study.
Benson R; Zhao SS; Goodson N; Abernethy R; Mewar D; Barnes T
Rheumatol Int; 2020 Jul; 40(7):1045-1049. PubMed ID: 32086605
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM
Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
[TBL] [Abstract][Full Text] [Related]
4. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
5. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W
Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
[TBL] [Abstract][Full Text] [Related]
6. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.
Choquette D; Bessette L; Alemao E; Haraoui B; Postema R; Raynauld JP; Coupal L
Arthritis Res Ther; 2019 Jun; 21(1):138. PubMed ID: 31171024
[TBL] [Abstract][Full Text] [Related]
7. Remission and low disease activity matrix tools: results in real-world rheumatoid arthritis patients under anti-TNF therapy.
Ganhão S; Lucas R; Fonseca JE; Santos MJ; Gonçalves DR; Madeira N; Silva C; Dourado E; Freitas R; Rodrigues J; Azevedo S; Rocha TM; Ferreira RM; Garcia S; Fernandes BM; Prata AR; Couto M; Torres RP; Cunha I; Costa L; Bernardes M
Acta Reumatol Port; 2020; 45(4):245-252. PubMed ID: 33420771
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry.
Sebba A; Bingham CO; Bykerk VP; Fiore S; Ford K; Janak JC; Pappas DA; Blachley T; Dave SS; Kremer JM; Yu M; Choy E
Clin Rheumatol; 2023 Aug; 42(8):2037-2051. PubMed ID: 37060528
[TBL] [Abstract][Full Text] [Related]
9. Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis.
Bass AR; Abdel-Wahab N; Reid PD; Sparks JA; Calabrese C; Jannat-Khah DP; Ghosh N; Rajesh D; Aude CA; Gedmintas L; MacFarlane L; Arabelovic S; Falohun A; Mushtaq K; Haj FA; Diab A; Shah AA; Bingham CO; Chan KK; Cappelli LC
Ann Rheum Dis; 2023 Jul; 82(7):920-926. PubMed ID: 37019614
[TBL] [Abstract][Full Text] [Related]
10. Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE).
Ceccarelli F; Massafra U; Perricone C; Idolazzi L; Giacomelli R; Tirri R; Russo R; Pistone G; Ruscitti P; Parisi S; Sainaghi PP; Cacciapaglia F; Zullo A; Marino V; Migliore A; Valesini G
Clin Exp Rheumatol; 2017; 35(1):24-32. PubMed ID: 27974105
[TBL] [Abstract][Full Text] [Related]
11. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
[TBL] [Abstract][Full Text] [Related]
12. Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-α Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study.
Dalén J; Luttropp K; Svedbom A; Black CM; Kachroo S
Adv Ther; 2020 Sep; 37(9):3746-3760. PubMed ID: 32647910
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
Akiyama M; Kaneko Y; Kondo H; Takeuchi T
Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
[TBL] [Abstract][Full Text] [Related]
14. Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data.
Pappas DA; Litman HJ; Lesperance T; Kricorian G; Karis E; Rebello S; Hua W; Accortt NA; Stryker S
Rheumatol Int; 2021 Feb; 41(2):381-390. PubMed ID: 32876744
[TBL] [Abstract][Full Text] [Related]
15. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.
Kihara M; Davies R; Kearsley-Fleet L; Watson KD; Lunt M; Symmons DP; Hyrich KL;
Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness and persistence of TNFi and non-TNFi in juvenile idiopathic arthritis: a large paediatric rheumatology centre in the USA.
Yue X; Huang B; Hincapie AL; Wigle PR; Li Y; Qiu T; Lovell DJ; Morgan EM; Guo JJ
Rheumatology (Oxford); 2021 Sep; 60(9):4063-4073. PubMed ID: 34469569
[TBL] [Abstract][Full Text] [Related]
17. Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers.
Lequerré T; Farran É; Ménard JF; Kozyreff-Meurice M; Vandhuick T; Tharasse C; Pouplin S; Daragon A; Le Loët X; Varin R; Vittecoq O
Joint Bone Spine; 2015 Oct; 82(5):330-7. PubMed ID: 25864942
[TBL] [Abstract][Full Text] [Related]
18. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
[TBL] [Abstract][Full Text] [Related]
19. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
[TBL] [Abstract][Full Text] [Related]
20. Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial.
Ruscitti P; Masedu F; Alvaro S; Airò P; Battafarano N; Cantarini L; Cantatore FP; Carlino G; D'Abrosca V; Frassi M; Frediani B; Iacono D; Liakouli V; Maggio R; Mulè R; Pantano I; Prevete I; Sinigaglia L; Valenti M; Viapiana O; Cipriani P; Giacomelli R
PLoS Med; 2019 Sep; 16(9):e1002901. PubMed ID: 31513665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
